9Th ANNUAL MEETING
Heidelberg • 2025

9th Meeting of the European Hereditary Tumour Group (EHTG)

Friday, Sept 19th – Sunday, Sept 21st, 2025

Heidelberg, Germany

Final Programme

Invitation 9th Meeting - Heidelberg

Dear Members, Friends, Affiliates and Sponsors,

We are delighted to welcome you to the 9th Annual EHTG Meeting, taking place from September 19–21, 2025, in Heidelberg – the renowned City of Science.

Join us for a dynamic and thought-provoking programme featuring cutting-edge and controversial topics, in-depth expert debates, and valuable insights from the patient perspective.

Beyond the scientific sessions, this year's meeting offers a unique opportunity to strengthen collaboration within our growing community.

We look forward to inspiring discussions, new connections, and shaping the future of hereditary tumour research together.

Please visit www.ehtg.org for more information and contact gs007@ehtg.org for all organisational queries.

We are excited to welcome you to Heidelberg in September!

Sincerely yours
EHTG programme committee and board members

Organisation

Board Members:

Aysel Ahadova (Germany)
Peter Bauerfeind (Switzerland)
John Burn (United Kingdom)
Mev Dominguez-Valentin (Norway)
Saskia Haupt (Germany)
Kelly Kohut (United Kingdom)
Florian Kühn (Germany)
Fiona Lalloo (United Kingdom)
Laura Monje-Garcia (United Kiddom)
Gabriela Möslein (Germany)
Neil Ryan (United Kingdom)
Julian Sampson (United Kingdom)
Toni Seppälä (Finland)

Programme Committee:

Florian Kühn (Germany, Programme Director)
Aysel Ahadova (Germany)
Ann-Sofie Backman (Sweden)
Richard Gallon (United Kingdom)
Elizabeth Half (Israel)
Neil Ryan (United Kingdom)
Laura Thomas (United Kingdom)

Secretariat:

Gabriele Sponholz
gs007@ehtg.org, +49 160 8459502
D-65207 Wiesbaden (Germany)

Location:

FRAUENBAD Heidelberg
Bergheimer Straße 45
69115 Heidelberg
+49 (0) 6221 651 5038
https://www.frauenbad-heidelberg.de/

Registration and Registration Fee:

See online via www.ehtg.org

Certification:

CME Accreditation (UEMS/EACCME):
18 credit points

LÄK Baden- Württemberg:
18 credit points Cat.B

Congress Organisation:

Miaglossa GmbH,
Pilgrimstraße 6, 50674 Köln

Content

Content

Meeting Overview

Day 1 – Friday, September 19th

Time	Event
10:00-12:05	Hereditary Cancer Syndromes for Clinicians – Essentials you need to know!
12:05-13:15	Opening Ceremony and Welcome Lunch
13:15-14:30	Current Surgical Indications in Hereditary Cancer Syndromes
14:30-16:00	Artificial Intelligence - The Future Decision Maker in Hereditary Cancer Syndromes?
16:00-16:20	Coffee Break
16:20-16:50	Panel Discussion: Personalized Screening in Hereditary Cancer?
16:50-17:10	Abstracts: Gastroenterology I
17:10-18:10	Spotlight on Pancreas
18:10-18:30	Abstracts: Gastroenterology II
18:30-18:40	Award Ceremony – Travel Grants
18:40 +	Get Together at FRAUENBAD, Heidelberg
20:00 +	Y-EHTG evening at URBAN KITCHEN

Meeting Overview

Day 2 – Saturday, September 20th

Time	Event
08:00-08:45	PLSD Business Meeting
08:45-09:40	Update on Guidelines
09:40-10:00	Coffee Break
10:00-11:40	Rethinking Genetics
11:40-12:00	E-health – the Future of Digital Medicine
12:00-13:00	Y-EHTG
13:00-13:50	Lunch
13:50-14:00	AWARD Ceremony – Y-EHTG
14:00-14:30	Keynote: Tracing the Life History of Colorectal Cancer with Hypermutable DNA
14:30-15:45	Liquid Biopsy
15:45-16:05	Coffee Break
16:05-17:30	Translational Immunology and Immunoprevention
17:30-17:50	Big Trends in MSI Research
17:50-18:30	EHTG Nursing Session
20:00 +	Conference Dinner at MOLKENKUR

Meeting Overview

Day 3 – Sunday, September 21st

Time	Event
08:30-09:00	EHTG Business Meeting
09:05-10:40	Prevention of the Preventable
10:40-11:05	Coffee Break
11:05-12:15	Patient Perspectives
12:15-13:30	Gynecological Tumors - Implications for Hormonal Status and Fertility
13:30-14:00	Lunch Break
14:00-14:30	My most Challenging Case
14:30-15:45	CMMRD - what's new?
15:45-16:00	Meeting Summary and Closing Remarks

Notes

Scientific Programme

Day 1 – Friday, September 19th

10:00-12:05	**Hereditary Cancer Syndromes for Clinicians – Essentials you need to know!** *Chairs: Neil Ryan (United Kingdom)* *Sonia Kupfer (USA)* *Naim Abu Freha (Israel)*
10:00-10:15	**Genetic Background of Hereditary Cancer Syndromes** *Laura Valle Velasco (Spain)*
10:15-10:30	**Diagnostics in MSI Tumors – IHC or PCR? Somatic or Germline?** *Matthias Kloor (Germany)*
10:30-10:45	**Gastroenterological Surveillance in Hereditary Cancer Syndromes** IJC UICC *Robert Hüneburg (Germany)*
10:45-11:00	**Therapeutic Management of Lynch Syndrome: Immunotherapy for everyone?** IJC UICC *Romain Cohen (France)*
11:00-11:15	**Basic Elements of Genetic Counselling for Hereditary Cancer** *Kelly Kohut (United Kingdom)*
11:15-11:35	**DISCUSSION**
11:35-12:05	**ABSTRACTS**
	Outcomes from the English National Health Service Lynch Syndrome Transformation Project: Nationally Coordinated Delivery of Universal Testing for Lynch Syndrome *and* **The New English National Bowel Cancer Screening Programme (BCSP) for Lynch Syndrome** *Kevin Monahan (United Kingdom)*
	Expanding Lynch Syndrome Spectrum: the Role of Non-Colorectal/Endometrial Malignancies and Implications for Universal Tumor Screening *and*

Scientific Programme

Day 1 – Friday, September 19th

Analysis of the Performance of Universal Tumor Screening for Lynch Syndrome on Consecutive 1022 Patients Resected for Colorectal Cancer.
Emanuele Urso (Italy)

Upper Gastrointestinal Surveillance in Lynch Syndrome
Katrin van Beekum (Germany)

Distinct Genomic Landscape, Constrained Hypermutation and Absence of TERT Promoter Mutations in Lynch Syndrome-Associated Urothelial Cancer
Jussi Nikkola (Finland)

12:05-13:15 **Opening Ceremony and Welcome Lunch**

Welcome Address
Gabriela Möslein (Chair)
Florian Kühn (Programme Director)
Aysel Ahadova (Local Host)

Introduction of the IJC Special Issue
Christoph Plass (Editor-in-Chief, IJC)

13:15-14:30 **Current Surgical Indications in Hereditary Cancer Syndromes**
Chairs: Gabriela Möslein, (Germany)
Florian Kühn (Germany)
Benedito Rossi (Brazil)

13:15-13:30 **Lynch Syndrome: do we still need Surgery?**
David Liska (USA)

13:30-13:45 **Surgical Intervention in Polyposis Syndromes - When is it Mandatory?**
Ashish Sinha (United Kingdom)

13:45-14:00 **Update on Technical Aspects of Surgery for FAP**
Yann Parc (France)

14:00-14:05 **DISCUSSION**

Scientific Programme

Day 1 – Friday, September 19th

14:05-14:20 **Debate: Prophylactic Gastrectomy for CDH1 Carriers**
Uberto Fumagalli Romario (Italy)
Ophir Gilad (USA)

14:20-14:30 ABSTRACTS

Risk of Desmoid Formation in FAP after Minimally Invasive versus Open Restorative Proctocolectomy
Benjamin Zare (United Kingdom)

The Impact of Hysterectomy on Subsequent Colonoscopy in Women with Lynch Syndrome.
Hanne Hyldebrandt (Norway)

14:30-16:00 **Artificial Intelligence - The Future Decision Maker in Hereditary Cancer Syndromes?**
Chairs: Magnus von Knebel Doeberitz (Germany)
Sanne Bajwa-ten Broeke (The Netherlands)

14:30-14:50 **Keynote: How to Employ AI to Fight Cancer?**
Julio Mayol (Spain)

14:50-15:05 **AI in Genetics**
Susanna Zucca (Italy)

15:05-15:20 **AI in Endoscopy**
Marco Spadaccini (Italy)

15:20-15:35 **AI in Histopathology - Helper or Killer?**
Peter Schirmacher (Germany)

15:35-15:45 **DISCUSSION**

15:45-16:00 ABSTRACTS

Evaluating the Potential of Artificial Intelligence-Based Algorithms to Predict Beta-2-Microglobulin Mutations in Mismatch Repair-Deficient Colorectal Cancer
Mozzam Motiwala (Germany)

Scientific Programme

Day 1 – Friday, September 19th

Evaluation of a RAG-based AI Chatbot for Neurofibromatosis Type 1 Using Simulated Patient Queries: a Genetic Counselor-Led Validation Study
Mashu Futagawa (Japan)

16:00-16:20 **Coffee Break**

16:20-16:50 **Panel Discussion: Personalized Screening in Hereditary Cancer?**

IJC | UICC

Sonia Kupfer (USA), Moderator
Kevin Monahan (United Kingdom)
Elizabeth Half (Israel)
Francesc Balaguer Prunés (Spain)
Elena Stoffel (USA)

16:50-17:10 **Abstracts: Gastroenterology I**
Chairs: Kevin Monahan (United Kingdom)
Elizabeth Half (Israel)

Adopting an Extended Interval Approach in Individuals with Lynch Syndrome Could Result in a High Rate of Interval Colorectal Cancer at Advanced Stage
Aharoni Golan (Israel)

Risk of Ileal Neoplasia in Lynch Syndrome Patients
Katrin van Beekum (Germany)

In Path_MMR Carriers, Diagnosis of Cancer in One Organ Does Not Modify the Probability for Cancer in Another Organ

and

Three Mechanisms May Explain Why Colonoscopy Does Not Reduce Colorectal Cancer Incidence in Three of the Four Lynch Syndromes
Pål Møller (Norway)

Scientific Programme

Day 1 – Friday, September 19th

17:10-18:05 **Spotlight on Pancreas**
Chairs: Ann-Sofie Backman (Sweden)
Imogen Bennett (United Kingdom)

17:10-17:25 **Who and How to Screen for Pancreatic Cancer?**
Matthias Löhr (Sweden)

17:25-17:40 **Long-term Yield of Pancreatic Cancer Surveillance in High-Risk Individuals**
Kasper Overbeek (The Netherlands)

17:40-17:55 **NGS-Based Treatment for Pancreatic Cancer - Indication and Success Rates**
Christoph Springfeld (Germany)

17:55-18:05 **DISCUSSION**

18:05-18:30 **Abstracts: Gastroenterology II**
Chairs: *Elena Stoffel (USA)*
Francesc Balaguer Prunés (Spain)
Stephanie Poo (United Kingdom)

Excellent Survival for Lynch Syndrome Individuals with Screen Detected Pancreatic Cancer and MMRD Status: Data from the PLSD
Hadar Edelman-Klapper (Israel)

Survival of Lynch Syndrome Patients with Biliary Carcinoma: Data from the PLSD
Lior H. Katz (Israel)

Duodenal Involvement in MUTYH-Associated Polyposis: Findings from an International Prospective Study and Implications for Endoscopic Surveillance
Imogen Bennett (United Kingdom)

Follow-Up, Cancer Risk and Mortality in Peutz-Jeghers Syndrome: a Cohort Study from the PRED-IdF Network
Maxime Remond (France)

Scientific Programme

Day 1 – Friday, September 19th

18:30-18:40	**Award Ceremony – Travel Grants**
18:40 +	**Get-Together at Frauenbad, Heidelberg**
20:00 +	**Y-EHTG evening at URBAN KITCHEN** (same building as Frauenbad) at your own expense!

Scientific Programme

Day 2 – Saturday, September 20th

08:00-08:45	**PLSD Business Meeting** *Chair: Mev Dominguez-Valentin (Norway)*
08:45-09:40	**Update on Guidelines** *Chairs: Mev Dominguez-Valentin (Norway)* *Kai-Keen Shiu (United Kingdom)*
08:45-09:00	**European Initiative on Harmonized Lynch Syndrome Guidelines** *Giulia Martina Cavestro (Italy)*
09:00-09:15	**EMQN Best Practice Guidelines for MSI** *Richard Gallon (United Kingdom)*
09:15-09:30	**Updated BRCA Guidelines (Gastrointestinal)** *Elizabeth Half (Israel)* *Zohar Levi (Israel)* *Lior Katz (Israel)*
09:30-09:40	**DISCUSSION**
09:40-10:00	**Coffee break**
10:00-11:40	**Rethinking Genetics** *Chairs: Maartje Nielsen (The Netherlands)* *Vince Kornel Grolmusz (Hungary)* *Romy Walker (Australia)*
10:00-10:15	**What is Universal about Testing: How We Do It and How We Should Do It?** *Heather Hampel (USA)*
10:15-10:30	**Cascade Testing Barriers: How to Overcome?** *Joanne Ngeow (Singapore)*
10:30-10:45	**Improving Genetic Diagnosis of Hereditary Tumor Diseases: From Expanded Gene Panels to Functional Genomics** *Barbara Klink (Germany)*

Scientific Programme

Day 2 – Saturday, September 20th

10:45-10:55 DISCUSSION

10.55-11.40 ABSTRACTS

Decoding Lynch Syndrome: Resolving Difficult to Categorize Findings in the DNA Mismatch Repair Genes MLH1, PMS2 and MSH2
Rodney Scott (Australia)

Improving Interpretation of POLE and POLD1 Exonuclease Domain Missense Variants via Functional Studies and AI-Based Pathogenicity Predictors
Laura Valle (Spain)

Extra-Intestinal Cancer Risk, Including Breast, Ovarian, and Endometrial Cancer, in MUTYH-Associated Polyposis (MAP)
Maartje Nielsen (The Netherlands)

Cancer Risks for ATM Variant Carriers in Ataxia-Telangiectasia Families and in Families Identified in Family Cancer Clinics
Fabienne Lesueur (France)

Testing *in vitro* Efficacy of Werner Helicase Inhibitors on Patient-Derived Tumor Organoid Models of Lynch Syndrome-Associated Colorectal Cancer
Julia Kolikova (Finland)

Characterisation of Rare Germline Genetic Variation in the RNF43 Gene in People with Serrated Polyposis Syndrome
Daniel Buchanan (Australia)

Phenotypic and Genotypic Profile of Lynch Syndrome in Latin America: A Multicenter Study
Mev Dominguez Valentin (Norway)

Comprehensive Germline and Somatic Analyses Delineate Mutational Mechanisms in Two Independent Patients Carrying a Combination of Germline Pathogenic Variants in APC and PMS2
Vince Kornel Grolmusz (Hungary)

Scientific Programme

Day 2 – Saturday, September 20th

Direct Letters to Relatives at Risk of Hereditary Cancer – A Multi-Center Randomized Trial on Healthcare-Assisted versus Family-Mediated Risk Disclosure (The Swedish DIRECT-Study)
Anna Rosen (Sweden)

11:40-12:00 **Keynote: E-health – the Future of Digital Medicine**
Introduction: John Burn (United Kingdom)
IJC UICC *Speaker: Magnus von Knebel Doeberitz (Germany)*

12:00-13:00 **Y-EHTG**
Chairs: Alethea Tang (United Kingdom)
Maria Rasmussen (Denmark)
Saskia Haupt (Germany)

12:00-12:15 **Introduction, Prizes, News**
Saskia Haupt (Germany)

12:15-13:00 **ABSTRACTS**

Whole Exome Sequencing of MLH1 Lynch Syndrome Colorectal Cancer Reveals Frequent Copy Number Alterations in MLH1-CTNNB1 Locus
Kalle Hokkanen (Finland)

Cancer Risks in First-Degree Relatives of Individuals with Biallelic Somatic DNA Mismatch Repair Mutations
Romy Walker (Australia)

Epigenetic Therapy for Mismatch Repair-Deficient Tumors
Anna Scheßl (Germany)

Evaluating Cost-Effectiveness of Preventive Strategies and the Impact of Specialized Care Pathways for Peutz-Jeghers Syndrome in Europe
Amalia Nicole Nanciu (Germany)

Scientific Programme

Day 2 – Saturday, September 20th

Description of the Coding Mutational Landscape Involved in the MSI Lynch Syndrome Colorectal Carcinogenesis, from Initiation (MMR-Deficient Crypts) to Tumor Progression (Adenoma, Adenocarcinoma)
Hugo Montémont (Germany)

Diving into Sex-Based Disparities: Systemic Biomarker Associations to Physical Activity in Lynch Syndrome Carriers
Minta Kärkkäinen (Finland)

PCR-Based Microsatellite Instability Testing: Pitfalls and Strategies for Enhancing Accuracy
Maria Kessler (Germany)

Study Plan: The Interplay Between Aging, Physical Activity and Immune Cells in Cancer Risk Regulation
Henna-Riikka Littunen (Finland)

Urological Malignancies in Lynch Syndrome
Antonia Schuler (Germany)

13:00-13:50	**Lunch**
13:50-14:00	**AWARD Ceremony – Y-EHTG**
14:00-14:30	**Keynote: Tracing the Life History of Colorectal Cancer with Hypermutable DNA** *Introduction: Aysel Ahadova (Germany)* *Speaker: Kamila Naxerova (USA)*
14:30-15:45	**Liquid Biopsy** *Chairs: Alessandro Mannucci (Italy)* *Alex Duval (France)* *Maria Rasmussen (Denmark)*
14:30-14:45	**New Horizons of Liquid Biopsy Analysis Using Blood and CSF for Patients with Cancer Predisposition Syndromes** *Uri Tabori (Canada)*

Scientific Programme

Day 2 – Saturday, September 20th

14:45-15:00 **PREDiLynch**
Mev Dominguez-Valentin (Norway
Toni Seppälä (Finland)

15:00-15:15 **Urine-Based Surveillance in Lynch Syndrome**
Michael Jackson (United Kingdom)

15:15-15:25 **DISCUSSION**

15:25-15:45 **ABSTRACTS**

Multi-Omics Approaches to Uncover Liquid-Biopsy-Based Cancer-Predicting Biomarkers in Lynch Syndrome
Tiina Jokela (Finland)

LIFE-CNA: A Whole-Genome Liquid Biopsy Approach Beyond Single Variant Detection in Diverse Tumour Entities

and

Liquid Biopsy Analysis of Advanced Breast Cancer Patients – A Real-life Perspective of Actionable Variants
Thomas Keßler (Germany)

Leveraging Ultra Low-Coverage Whole Genome Sequencing in Liquid Biopsy for Early Cancer Screening: Insights from the PreveLynch Cohort
Tomas Szemes (Slovakia)

15:45-16:05 **Coffee break**

16:05-17:30 **Translational Immunology and Immunoprevention**
Chairs: Matthias Kloor (Germany)
Stefanie Bärthel (Germany)
Henna-Riikka Littunen (Finland)

16:05-16:20 **Cancer Immunoprevention Approaches: Current Status**
Steve Lipkin (USA)

Scientific Programme

Day 2 – Saturday, September 20th

16:20-16:35 **Organ-Sparing Therapy Options for Patients with Inherited Cancers – Decision Making and Patient Outcomes**
Antoine Dardenne (France)

16:35-16:50 **Panel Discussion: Perfect Vaccine: How Does It Look? Why We Need Vaccines in the Era of Immunotherapy?**
Speakers and Chairs

16:50-17:30 **ABSTRACTS**

Immune Surveillance in Lynch Syndrome: T Cell Receptor Repertoire Mapping and Clonal Expansion in Colorectal Neoplasia
Penelope Edwards (United Kingdom)

Microsatellite Instability Degree and Immunological Profile of MSH6-mutated Colorectal Carcinomas compared to other Lynch Syndrome-Associated Colorectal Carcinomas
Noah Cornelis Helderman (The Netherlands)

Unveiling Immune Surveillance in Lynch Syndrome: Insights from T cell Population Characterization
Joaquin Andres Castillo (Spain)

HLA Fine-Mapping and Immunopeptidome-Wide Association Studies Identify Functional Colorectal Cancer Risk Modifiers and Frameshift Neoantigen Targets in Lynch Syndrome
Aaron Meyers (Australia)

HLA Genotypes as a Potential Cancer Risk Modifiers in Women Living with Germline Pathogenic BRCA1 Variants
Marcell Kakonyi (Hungary)

Scientific Programme

Day 2 – Saturday, September 20th

17:30-17:50 **Keynote: Big Trends in MSI Research**
Introduction: Matthias Kloor (Germany)
Speaker: Alex Duval (France)

17:50-18:30 **EHTG Nursing Session**
Chairs: Laura Monje-Garcia (United Kingdom)
Mechelle Loughrey (Ireland)

17:50-18:00 **Nursing Innovation in Hereditary Cancer: Advancing Scope, Genomics, and Research Within the Multidisciplinary Team**
Mechelle Loughrey (Ireland)

18:00-18:30 ABSTRACTS

Opening Pandora's Box: A Qualitative Study on the Psychological Impacts of Living with an Inherited Colorectal Cancer Predisposition Syndrome (PSYLIVED)
Laura Monje-Garcia (United Kingdom)

Implementation of Mainstream Lynch Syndrome Testing in a High-Volume Colorectal Cancer Service: Outcomes from a UK Tertiary Centre
Helen Francis (United Kingdom)

Declining Genetic Testing Uptake among Individuals from Lynch Syndrome and Hereditary Breast and Ovarian Cancer Families
Elizabeth Half (Israel)

Evening Programme

Conference Dinner at MOLKENKUR

Saturday, September 20, 20:00

Arrival:
Individual arrival by foot walking through the Old Town, followed by a ride on the historic funicular railway from Kornmarkt to Molkenkur.

Departure:
Return to hotels via staggered bus transfers between 22:30 and 24:00.

The Schlosshotel Molkenkur is located above the Heidelberg Castle, surrounded by nature and offering a sensational panoramic view over the Rhine plain.

A Brief History of Molkenkur
The so-called "Upper Castle," located on the present-day Molkenkur parking area, was the original Heidelberg Castle, first mentioned in records in 1225. After the construction of the "New Castle," the old structure was struck by lightning and destroyed on April 25, 1537.

In 1851, Albrecht Wagner began construction of what is now known as the Swiss House, the central building of the Molkenkur complex. This structure is a listed heritage building and has remained nearly unchanged since its completion.

The name Molkenkur comes from the "whey cure" (Molkenkur in German) – a once-popular therapeutic treatment using dairy products that gave the site its name and historical significance as a health retreat.

Scientific Programme

Day 3 – Sunday, September 21th

08:30-09:00 **EHTG Business Meeting**
Chairs: *Toni Seppälä (Finland)*
Gabriela Möslein (Germany)

09:00-10:40 **Prevention of the preventable**
Chairs: C. Richard Boland (USA)
Heather Hampel (USA)
Kelly Kohut (United Kingdom)

09:00-09:15 **Addressing Lifestyle Factors to Prevent Cancer in High-Risk Individuals**
John Mathers (United Kingdom)

09:15-09:30 **Patients' Preference for Preventative Strategies / Uptake of Aspirin for Lynch Syndrome Chemoprevention**
Michael Hall (USA)

09:30-09:45 **Is Less More? CAPP3 Data on Aspirin for Cancer Prevention in Lynch Syndrome**
IJC | UICC
John Burn (United Kingdom)

09:45-10:00 **Mesalamine-based Prevention of Inherited Cancer**
Ann-Sofie Backman (Sweden)

10:00-10:15 **Employing Microbiota to Prevent Cancer in Hereditary Tumor Syndromes**
Phil Quirke (United Kingdom)

10:15-10:25 **DISCUSSION**

10:25-10:40 **ABSTRACTS**

Linking Lynch Syndrome Mutations to the Gut Microbiome Profile: A Predictive Approach for Colorectal Cancer Risk
Elizabeth Half (Israel)

Association between Blood Levels of Selenium, Zinc and Copper and Survivalin Colorectal Cancer Patients with Lynch Syndrome
and

Scientific Programme

Day 3 – Sunday, September 21th

SELINA – Lowering of Cancer Risk and All-Cause Mortality by Optimization of Se and As Blood Levels in Females from Families with Hereditary Breast Cancer
Jan Lubinski (Poland)

10:40-11:05 **Coffee break**

11:05-12:15 **Patient Perspectives**
Chairs: Kelly Khout (United Kingdom)
Georgina Hoffmann (Germany)

Coping with Lynch syndrome – Patient Perspectives

11:05-11:15 **Modifiable Lifestyle Factors**
Aung Ko Win (Australia)

11:15-11:20 **Interview and Panel Discussion**
What is Helping Us Living with Lynch and Facing Our Lifelong Cancer Risk? Where Do We See Gaps in Care and Support?
Georgina Hoffmann (Germany)

11:20-11:25 **Lynch Choices:**
https://canchoose.org.uk/ Decision Aid Tool
Kelly Kohut (United Kingdom)

11:25-11:30 **Lynch Syndrome UK**
Tracy Smith (United Kingdom)

11:30-11:45 **Raising Detection: Finding the Missing 95%**
ALL PATIENT ORGANIZATIONS

Lynch syndrome Awareness: Achievements and Future Aspiration

11:45-11:50 **Awareness Campaigns Alive and Kick'n**
Dave Dubin (USA)

11:50-11:55 **Awareness Campaign Lynch Syndrome Ireland**
Roberta Horgan (Ireland)

11:55-12:00 **Awareness Campaign SemiColon**
Georgina Hoffmann (Germany)
Nicola Reents (Germany)

12:00-12:05 **DISCUSSION**

Scientific Programme

Day 3 – Sunday, September 21th

12:05-12:15 ABSTRACTS

Addressing the Psycho-Social Needs of Hereditary Cancer Risk Patients: "A Much Needed Specialist Service"
Louise O'Driscoll (Ireland)

Impact of Risk-Reducing Hysterectomy on Health-Related Quality of Life in Lynch Syndrome Women: PRESCORES Study
Ranjit Manchanda (United Kingdom)

12:15-13:30 **Gynecological Tumors – Implications for Hormonal Status and Fertility**
Chairs: Denise Nebgen (USA)
Neil Ryan (United Kingdom)
André Pfob (Germany)

12:15-12:30 **Perspectives on Early Detection Strategies**
Neil Ryan (United Kingdom)

12:30-12:45 **Risk-Reducing Bilateral Salpingo- Oophorecto my for Ovarian Cancer and Opportunties for Novel Screening Approaches**
Zsofia Stadler (USA)

12:45-13:00 **Fertility Preservation in Patients with BRCA Mutations or Lynch Syndrome**
Claudia Marchetti (Italy)

13:00-13:15 **Keynote: Population Screening Strategies and the Implications of the PROTECTOR Study**
Ranjit Manchanda (United Kingdom)

13:15-13:30 ABSTRACTS

What are the Lifetime Endometrial Cancer Risk Thresholds for Surgical and Medical Prevention of Endometrial Cancer and Estimating its Cost-Effectiveness
Ranjit Manchanda (United Kingdom)

A New Method of Screening Female Lynch Syndrome Carriers for Endometrial Cancer: The Ellele Sampling Device

and

Scientific Programme

Day 3 – Sunday, September 21th

MicrosatEllite Womb Surveillance (MEWS) Study
Neil Ryan (United Kingdom)

13:30-14:00 **Lunch**

14:00-14:30 **My most Challenging Case**
Chairs: Giulia Martina Cavestro (Italy)
Toni Seppälä (Finland)

Somatic PTEN Mosaicism in Colorectal Polyposis Patients
Diantha Terlouw (The Netherlands)

A Challenging Case of Gastric Cancer in an Elderly CDH1 Mutation Carrier Without a Family History
Hadar Edelman-Klapper (Israel)

Distal Cholangiocarcinoma Arising in Familial Adenomatous Polyposis: A Unique Case Presentation
Julius Hüneburg (Germany)

The Dark and the Light. The Difficult Journey of a Patient with a Huge Cancer of the Ascending Colon and Lynch Syndrome.
Emanuele Urso (Italy)

14:30-15:30 **CMMRD - what's new?**
Chairs: Gabriel Capella (Spain)
Chrystelle Colas (France)
Steve Lipkin (USA)

14:30-14:45 **ERN GENTURIS Guidelines**
Chrystelle Colas (France)
Katharina Wimmer (Austria)

14:45-15:00 **Care for CMMRD Database**
Pauline Hoarau (France)

15:00-15:15 **Updates from IRRDC: From Expanding Landscapes to Novel Therapies**
Anirban Das (Canada)

Scientific Programme

Day 3 – Sunday, September 21th

15:15-15:20	DISCUSSION
15:20-15:35	ABSTRACTS
	Modelling the Origin of Glioblastoma in Constitutional Mismatch Repair Deficiency Syndrome *Manuel Torralba (Spain)*
	Screening Program to Improve Identification of Constitutional Mismatch Repair Deficiency in Spain *Oscar Mesia Carbonell (Spain)*
	First Report of POLD1 Homozygote Patient with Double Colon Cancer and Polyposis *Salwa Ben Yahia (The Netherlands)*
15:35-15:45	DISCUSSION
15:45-16:00	**Meeting Summary and Closing Remarks** *Gabriela Moeslein (Germany)* *Toni Seppälä (Finland)*

Notes

Poster Exhibition

Abu Shtaya, Aasem Israel	POT1 Variants: Drivers of Telomeric Elongation, Diverse Malignancies, and High Tumor Burden
Akdeniz, Bayram Norway	Understanding Cancer Risk Variability in Lynch syndrome: The Role of Polygenic Risk Scores
Aswolinskiy, Witali Germany	Interpretable Deep Learning for Microsatellite Instability Prediction in Colorectal Cancer From H&E-stained Whole Slide Images
Avsec, Eva Slovenia	Mismatch Repair Deficient Breast Cancer in Patients with Lynch syndrome
Bulbaai, Marjolein The Netherlands	Fish Intake and Colorectal Neoplasm Risk in Individuals with Lynch syndrome
Butz, Henriett Hungary	When Two Is Not Enough: Complexity of Cancer Patients with Multiple Germline Mutations in Tumour-Predisposing Genes
Campoy, Séphora France	Systematic Review and Meta-analysis of Lifetime Cancer Risk in Lynch syndrome: Impact of Methodology and Study Design
Colas, Crystelle France	Prevalence of Somatic Mosaicism in the APC Gene in Patients with Unexplained Colorectal Adenomatous Polyposis or Multiple Adenomatous Colorectal Polyps.
Dardenne, Antoine France	Cancer Incidence and Relevance of Surveillance Recommandation in Lynch syndrome Patients followed in a Specialized Resource Center
Dominguez Valentin, Mev Norway	Microsatellite Instability and Hereditary Risk in Ovarian Cancer

Poster Exhibition

Erisen, Gizem Mehtap Germany	Spatial Heterogeneity of Primary Lynch syndrome-associated Cancers.
Erkan, Erdogan Pekcan Finland	Single Cell Profiling of Tissue and Tumor Microenvironments in Mismatch Repair Deficient Colorectal Cancers
Fritzell, Kaisa Sweden	Impact on Mental and Physical Health, and Well-being in Patients with Polyposis Syndromes: A Scoping Review
Fujita, Hiroko Japan	Genetic Counselling for three Japanese Families with Gastric Adenocarcinoma and Proximal Polyposis of the Stomach (GAPPS)
Guillen Ponce, Carmen Spain	Cascade Testing of Low and Moderate Risk Genes in Hereditary Breast and Ovarian Cancer Syndrome.
Guillen Ponce, Carmen Spain	Pathogenic Variants in Patients with Early-onset Gastrointestinal Cancer.
Hirasawa, Akira Japan	Prospective Cohort Study with a Biobank for Hereditary Tumor Syndromes in Japanese -Mid-West Japan Hereditary Tumor Cohort-
Kobrow, Christian Germany	Transformation Behavior of Images in Latent Space
Lautrup, Charlotte Kvist Denmark	New RPS20 Gene Variant Underpins – the Role of RPS20 as a Colorectal Cancer Predisposition Gene without Extracolonic Manifestations
Lubinski, Jan Poland	Elements Ratio as a Marker of Cancer Risk and Mortality in BRCA1 Mutation Carriers.

Poster Exhibition

Monahan, Kevin United Kingdom	Diagnostic Yield of Genetic Testing and Risk Factors for Colorectal Cancer in Patients with Serrated Polyposis Syndrome
Montémont, Hugo Germany	Immunoguided Laser-Assisted Microdissection for Whole Exome and RNA-Sequencing: A Precise Technology to Explore Genomics and Transcriptomics Alteration in Early Stage of Cancer
Olkinuora, Alisa Switzerland	Exome Sequencing Study identifies DNA Glycosylase Gene Variants enriched in Swiss Colon Polyposis Patients
Poo, Stephanie United Kingdom	Colonoscopy Yield in Lynch Syndrome at a UK Tertiary Centre with High Baseline Quality Metrics
Ryan, Neil United Kingdom	A Mismatch in Testing: A Retrospective Analysis of Mismatch Repair Testing in Endometrial Cancer and Lynch syndrome Diagnosis in Multiple Specialist Centres in the UK and Ireland (March 2022–March 2023)
Silva, Sofia Spain	NGS and all that it reveals
Tada, Haruka Japan	A Parent-child case of Peutz-Jeghers Syndrome: Definitive Diagnosis using Microarray Chromosomal Analysis and Subsequent Surveillance
Urakawa, Yusaku Japan	Late-Onset Ovarian Cancer in BRCA2 Carriers: Rethinking Age Thresholds for Risk Reducing Surgery.

Poster Exhibition

Urso, Emanuele Italy	Analysis of a Consecutive Series of 402 Cases discussed at the Multi-disciplinary Oncology Group for Hereditary Gastrointestinal Tumors (GOM-TEGI) at the University Hospital of Padua - Veneto Institute of Oncology
Valle, Laura Spain	APC I1307K and Clinical Management: Insights from UK Biobank on Colorectal and other Cancer Risks in Ashkenazi and Non-Ashkenazi Whites
van der Werf-'t Lam, Anne-Sophie The Netherlands	Cancer Risks for MSH6 Pathogenic Variant Carriers

Faculty

Abu Freha, Naim p 10	Soroka University Medical Center Gastroenterology Assuta Beer-Sheva, Israel
Abu Shtaya, Aasem p 30	Rabin Medical Center Recanati Genetics Institute Petach Tikva, Israel
Ahadova, Aysel p 11, 19	Heidelberg University Hospital Heidelberg, Germany
Aharoni Golan, Maya p 13	Kaplan Medical Center Department of Gastroenterology and Hepatology Rehovot, Israel
Akdeniz, Bayram p 30	Oslo University Hospital, Department of Tumor Biology, Institute for Cancer Research Oslo, Norway
Aswolinskiy, Witali p 30	PAICON GmbH Heidelberg, Germany
Avsec, Eva p 30	Institute of Oncology Ljubljana, Slovenia
Backman, Ann-Sofie p 14, 24	Karolinska Institute Stockholm, Sweden
Bärthel, Stefanie p 20	BioMed X Institute Heidelberg, Germany
Balaguer Prunés, Francesc p 14	Clínic Barcelona - IDIBAPS Gastroenterology Department Barcelona, Catalonia, Spain
Bajwa-ten Broeke, Sanne p 12	University Medical Center Groningen Groningen, The Netherlands
Ben Yahia, Salwa p 28	Leiden University Medical Center Dpt. of Genetics Leiden, The Netherlands
Bennett, Imogen p 14	Swansea University Institute of Life Science 1 Swansea, United Kingdom

Faculty

Boland, C. Richard p 24	Prof. emer., University of California Department of Medicine, San Diego, USA
Buchanan, Daniel p 17	University of Melbourne Melbourne, Australia
Bulbaai, Marjolein p 30	Wageningen University & Research Division of Human Nutrition and Health Wageningen, Netherlands
Burn, John p 18, 24	Newcastle University, Translational and Clinical Research Institute Newcastle, United Kingdom
Butz, Henriett p 30	National Institute of Oncology Budapest, Hungary
Campoy, Séphora p 30	Centre Léon Bérard Department of Prevention and Public Healthcare Lyon, France
Capella, Gabriel p 27	Catalan Institute of Oncology IDIBELL Hospitalet de Llobregat, Spain
Castillo, Joaquin Andres p 21	Hospital Clínic de Barcelona Dpt. of Gastreoenterology Barcelona, Spain
Cavestro, Giulia Martina p 16, 27	IRCCS San Raffaele Scientific Institute, Gastroenterology and Gastrointestinal Endoscopy Unit Milan, Italy
Cohen, Romain p 10	University Department of medical oncology Paris, France
Colas, Chrystelle p 27	Institut Curie, Dpt. of Genetic Paris, France
Dardenne, Antoine p 21, 30	APHP - St. Antoine Service de gastroentérologie et d'oncologie digestive Paris, France

Faculty

Das, Anirban p 28	The Hospital for Sick Children Div. of Haematology, Oncology, Dpt. of Paediactrics Toronto, Canada
Dominguez-Valentin, Mev p 16, 17, 20, 30	Oslo University Hospital Department of Tumor Biology, Institute for Cancer Research Oslo, Norway
Dubin, David p 25	AliveAndKickn Lynch Syndrome Foundation Haworth, USA
Duval, Alex p 19, 22	APHP - St. Antoine, Sorbonne University Paris, France
Edelman-Klapper, Hadar p 14, 27	Rabin Medical Center Division of Gastroenterology Petah Tikva, Israel
Edwards, Penelope p 21	Institute of Cancer Research London, United Kingdom
Erisen, Gizem Mehtap p 31	Heidelberg University Hospital Department of Applied Tumor Biology Heidelberg, Germany
Erkan, Erdogan Pekcan p 31	Tampere University Tampere, Finland
Francis, Helen p 22	University College London Hospitals (UCLH) London, United Kingdom
Fritzell, Kaisa p 31	Karolinska Institute Huddinge, Sweden
Fujita, Hiroko p 31	Himeji Hospital Japanese Red Cross Society Himeji, Japan
Fumagalli Romario, Uberto p 12	European Insitute of Oncology - IRCCS, Dpt. of Digestive Surgery Milan, Italy

Faculty

Futagawa, Mashu p 13	Okayama University Department of Clinical Genomic Medicine Okayama, Japan
Gallon, Richard p 16	Newcastle University Newcastle, UK
Gilad, Ophir p 12	University of Chicago Section of Gastroenterologoy, Hepatology and Nutrition Chicago, IL, USA
Grolmusz, Vince Kornel p 16, 17	National Institute of Oncology Department of Molecular Genetics Budapest, Hungary
Guillen Ponce, Carmen p 31	Hospital Ramón y Cajal Madrid, Spain
Half, Elizabeth p 13, 16, 22, 24	Rambam Medical Center Cancer prevention Institute Haifa, Israel
Hall, Michael p 24	Fox Chase Cancer Center Philadelphia, PA, USA
Hampel, Heather p 24	City of Hope, Division of Clinical Cancer Genomics Duarte, CA, USA
Haupt, Saskia p 18	Heidelberg University Hospital Heidelberg, Germany
Helderman, Noah Cornelis p 21	Leiden University Medical Center Leiden, The Netherlands
Hirasawa, Akira p 31	Okayama University Okayama, Japan
Hoarau, Pauline p 27	Institut Gustave Roussy Villejuif, France
Hoffmann, Georgina p 25	SemiColon / ERN GENTURIS Schorndorf, Germany
Hokkanen, Kalle p 18	Tampere University Faculty of Medicine and Health Technology Tampere, Finland

Faculty

Horgan, Roberta p 25	Lynch Syndrome Ireland
Hüneburg, Julius p 27	University Hospital Bonn Department of Internal Medicine I Bonn, Germany
Hüneburg, Robert p 10	University Hospital Bonn Department of Internal Medicine I Bonn, Germany
Hyldebrandt, Hanne p 12	Oslo University Hospital Oslo, Norway
Jackson, Michael p 20	Newcastle University Biosciences Institute Newcastle, United Kingdom
Jokela, Tiina p 20	University of Jyväskylä Jyväskylä, Finland
Kakonyi, Marcell p 21	National Institute of Oncology Budapest, Hungary
Kärkkäinen, Minta p 19	University of Jyväskylä Jyväskylä, Finland
Katz, Lior H. p 14, 16	Hadassah Medical Center Jerusalem, Israel
Kessler, Maria p 19	Heidelberg University Hospital Department of Applied Tumor Biology Heidelberg, Germany
Keßler, Thomas p 20	MGZ – Medizinisch Genetisches Zentrum Munich, Germany
Klink, Barbara p 16	MGZ – Medizinisch Genetisches Zentrum Munich, Germany
Kloor, Matthias p 10, 20	Heidelberg University Hospital Department of Applied Tumor Biology Heidelberg, Germany

Faculty

Kobrow, Christian p 31	Heidelberg University Hospital Department of Applied Tumor Biology Heidelberg, Germany
Kohut, Kelly p 10, 24, 25	Department of Clinical and Biomedical Sciences, University of Exeter Medical School Exeter, United Kingdom
Kolikova, Julia p 17	University of Helsinki Helsinki, Finland
Kühn, Florian p 11	Department of General, Visceral and Transplantation Surgery University Hospital of LMU Munich Munich, Germany
Kupfer, Sonia p 10, 13	University of Chicago Department of Medicine, Section of Gastroenterology, Hepatology and Nutrition Chicago, IL, USA
Lautrup, Charlotte Kvist p 31	Vejle Hospital Department of Clinical Genetics Vejle, Denmark
Lesueur, Fabienne p 17	Institut Curie Inserm U1331 Paris, France
Levi, Zohar, p 16	Rabin Medical Center Div. of Gastroenterology Ganey Tikva, Israel
Lipkin, Steve p 20, 27	Weill Cornell Medicine Department of Medicine New York, NY, USA
Liska, David p 11	Weiss Center for Hereditary Colorectal Neoplasia, Department of Colorectal Surgery Cleveland Clinic Cleveland, Ohio
Littunen, Henna-Riikka p 19, 20	University of Jyväskylä Finland

Faculty

Löhr, Matthias p 14	Karolinska Institute Dpt. of Gastroenterology & Hepatology Stockholm, Sweden
Loughrey, Mechelle p 22	St. Vincent's University Hospital Dublin, Ireland
Lubinski, Jan p 24, 25, 31	Pomeranian Medical University Szczecin, Poland
Manchanda, Ranjit p 26	Queen Mary University of London Wolfson Institute of Population Health London, United Kingdom
Mannucci, Alessandro p 19	IRCCS San Raffaele Hospital Milano, Italy
Marchetti, Claudia p 26	Policlinico Universitario Agostino Gemelli IRCCS Dpt. of Gynecology Roma, Italy
Mathers, John p 24	Newcastle University Newcastle, United Kingdom
Mayol, Julio p 12	Universitad Complutense, Hospital Clinico San Carlos Dpt. of Surgery Madrid, Spain
Mesia Carbonell, Oscar p 28	Catalan Institute of Oncology IDIBELL Hereditary Cancer Programme L'Hospitalet de Llobregat, Spain
Meyers, Aaron p 21	University of Melbourne Melbourne, Australia
Møller, Pål p 13	The Norwegian Radium Hospital Department of Tumour Biology Oslo, Norway
Monahan, Kevin p 10, 13	Imperial College London Lynch Syndrome and Family Cancer Clinic St Mark's Hospital London, United Kingdom

Faculty

Monje-Garcia, Laura p 22	Imperial College London London, United Kingdom
Montemont, Hugo p 19, 32	Heidelberg University Hospital Department of Applied Tumor Biology Heidelberg, Germany
Möslein, Gabriela p 11, 24, 28	Bethesda University Hospital Duisburg, Germany
Motiwala, Mozzam p 12	Heidelberg University Hospital Department of Applied Tumor Biology Heidelberg, Germany
Nanciu, Amalia Nicole p 18	University Hospital Bonn Institute of Human Genetics Bonn, Germany
Naxerova, Kamila p 19	Harvard Medical School Dpt. of Genetics Boston, MA, USA
Nebgen, Denise p 26	University of Texas MD Anderson Cancer Center Houston, TX, USA
Ngeow, Joanne p 16	Nanyang Technological University Singapore National Cancer Centre Singapore Singapore, Singapore
Nielsen, Maartje p 16, 17	Leiden University Medical Center Department of Clinical Genetics Leiden, The Netherlands
Nikkola, Jussi p 11	Tampere University and Tays Cancer Centre, Faculty of Medicine and Health Technology Tampere, Finland
O'Driscoll, Louise p 26	St Vincent's University Hospital Dublin, Ireland
Olkinuora, Alisa p 32	University Hopsital Basel Institute for Medical Genetics and Pathology Basel, Switzerland

Faculty

Overbeek, Kasper p 14	Erasmus University Medical Center Dpt.of Gastroenterology & Hepatology Rotterdam, The Netherlands
Parc, Yann p 11	APHP - St. Antoine, Sorbonne University Paris, France
Pfob, André p 26	Heidelberg University Hospital Breast Center Heidelberg, Germany
Plass, Christoph p 11	International Journal of Cancer (IJC), DKFZ, Heidelberg, Germany
Poo, Stephanie p 14, 32	St. Mark's Hospital Imperial College London, United Kingdom
Quirke, Phil p 24	University of Leeds Leeds, United Kingdom
Rasmussen, Maria p 18, 19	Copenhagen University Hospital The Danish HNPCC Register Hvidovre, Denmark
Reents, Nicola p 25	SemiColon Bonn, Germany
Remond, Maxime p 14	Hôpital Cochin Paris, France
Rosen, Anna p 18	Umeå University Department of Diagnostics and Intervention, Oncology Umeå, Sweden
Rossi, Benedito p 11	Hospital Beneficência Portuguesa de São Paulo Sao Paulo, Brazil
Ryan, Neil p 10, 26, 27, 32	University of Edinburgh Edinburgh, United Kingdom

Faculty

Scheßl, Anna p 18	Heidelberg University Hospital Department of Applied Tumor Biology Heidelberg, Germany
Schirmacher, Peter p 12	Heidelberg University Hospital Institute of Pathology Heidelberg, Germany
Schuler, Antonia p 19	University Hospital Bonn Department of Internal Medicine I Bonn, Germany
Scott, Rodney p 17	Newcastle University Dpt. of Medical Genetics Newcastle, Australia
Seppälä, Toni p 20, 24, 27, 28	Tampere University Dpt. of Gastroenterology and Alimentary Tract Surgery Tampere, Finland
Shiu, Kai-Keen p 6	UCL Cancer Institute Faculty of Medical Sciences London, United Kingdom
Silva, Sofia p 32	CHUAC A Coruña, Spain
Sinha, Ashish p 11	St Mark's Hospital Dpt. of Surgery London, United Kingdom
Smith, Tracy, p 25	Lynch Syndrome UK Caerphilly, United Kingdom
Spadaccini, Marco p 12	Humanitas Research Hospital IRCCS Dpt. of Gastroenterology Milano, Italy
Springfeld, Christoph p 14	Heidelberg University Hospital Heidelberg, Germany
Stadler, Zsofia p 26	Memorial Sloan Kettering Cancer Center New York, NY, USA

Faculty

Stoffel, Elena p 13	University of Michigan Ann Arbor, MI, USA
Szemes, Tomas p 20	Geneton s.r.o. Genomics Core Laboratory Bratislavva, Slovakia
Tabori, Uri p 19	The Hospital for Sick Children Div. of Haematology/Oncology Toronto, Canada
Tada, Haruka p 32	Himeji Red Cross Hospital, Himeji City, Japan
Tang, Alethea p 18	Swansea University Institute of Life Sciences Swansea, United Kingdom
Terlouw, Diantha p 27	Leiden University Medical Center Department of Pathology Leiden, The Netherlands
Torralba, Manuel p 28	Catalan Institute of Oncology IDIBELL Hereditary Cancer Programme L'Hospitalet de Llobregat, Spain
Urakawa, Yusaku p 32	Okayama University Okayama, Japan
Urso, Emanuele p 10, 11, 27, 33	Università di Padova Chirurgia Generale 3-Azienda Ospedaliera Padova, Italy
Valle, Laura p 10, 32	Catalan Institute of Oncology IDIBELL Hereditary Cancer Programme L'Hospitalet de Llobregat, Spain
van Beekum, Katrin p 11, 13	University Hospital Bonn National Center for Hereditary Tumor Syndromes Bonn, Germany
van der Werf-'t Lam, Anne-Sophie p 32	Leiden University Medical Center Leiden, Netherlands

Faculty

von Knebel Doeberitz, Magnus p 12, 18	Heidelberg University Hospital Heidelberg, Germany
Walker, Romy p 16, 18	The University of Melbourne Department of Clinical Pathology Melbourne, Australia
Wimmer, Katharina p 27	Medical University Innsbruck Institute of Human Genetics Innsbruck, Austria
Win, Aung Ko p 25	University of Melbourne, Melbourne School of Population and Global Health Melbourne, Australia
Zare, Benjamin p 12	St Mark's Hospital Centre for Familial Intestinal Cancer London, United Kingdom
Zucca, Susanna p 12	enGenome SRL Pavia, Italy

Sponsors

We gratefully acknowledge the generous support of our sponsors, whose contributions make EHTG 2025 possible. Your partnership helps us advance research, foster collaboration, and drive innovation in hereditary tumor research and clinical management.

illumina®

8.000 EUR

https://www.illumina.com

MGZ
Medizinisch Genetisches Zentrum

8.000 EUR

www.mgz-muenchen.de

SpringWorks® THERAPEUTICS

4.000 EUR

www.springworkstx.com

Johnson&Johnson MedTech

1.000 EUR

www.jnjmedtech.de

The industry sponsors have provided unrestricted financial support.

Imprint

Responsible in accordance with press law:
Prof. Dr. med. Gabriela Moeslein
Evangelisches Bethesda Krankenhaus
Zentrum für Hereditäre Tumorerkrankungen
47053 Duisburg
gabriela.moeslein@ehtg.org

Organisation:
EHTG secretariat: Gabriele Sponholz, gs007@ehtg.org
Miaglossa GmbH, Köln, support@miaglossa.com

Partnership

IJC | UICC
International Journal of Cancer

Heidelberg Marketing

SemiColon
Netzwerk für Menschen
mit Lynch-Syndrom
und erblichem Darmkrebs

European Reference Network
for rare or low prevalence complex diseases
Network Genetic Tumour Risk Syndromes (ERN GENTURIS)

Image Credits

Cover: PantherMedia (now Smartpix)
Page 15: FRAUENBAD, Heidelberg
Page 23: MOLKENKUR, Heidelberg

We are excited to see you in Heidelberg!